559 related articles for article (PubMed ID: 30347498)
1. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.
Van Matre ET; Reynolds PM; MacLaren R; Mueller SW; Wright GC; Moss M; Burnham EL; Ho PM; Vandivier RW; Kiser TH
J Thromb Haemost; 2018 Dec; 16(12):2492-2500. PubMed ID: 30347498
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
3. Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma.
Jacobs BN; Cain-Nielsen AH; Jakubus JL; Mikhail JN; Fath JJ; Regenbogen SE; Hemmila MR
J Trauma Acute Care Surg; 2017 Jul; 83(1):151-158. PubMed ID: 28426561
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients.
Rothberg MB; Pekow PS; Lahti M; Lindenauer PK
J Hosp Med; 2012; 7(6):457-63. PubMed ID: 22473716
[TBL] [Abstract][Full Text] [Related]
5. Comparison of pharmacologic prophylaxis in prevention of venous thromboembolism following total knee arthroplasty.
Richardson SS; Schairer WW; Sculco PK; Bostrom MP
Knee; 2019 Mar; 26(2):451-458. PubMed ID: 30700390
[TBL] [Abstract][Full Text] [Related]
6. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Rutjes AW; Porreca E; Candeloro M; Valeriani E; Di Nisio M
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD008500. PubMed ID: 33337539
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry.
Donath L; Lützner J; Werth S; Kuhlisch E; Hartmann A; Günther KP; Weiss N; Beyer-Westendorf J
Br J Clin Pharmacol; 2012 Dec; 74(6):947-58. PubMed ID: 22515679
[TBL] [Abstract][Full Text] [Related]
9. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Ferrante N; Otten HM; Cuccurullo F; Rutjes AW
Cochrane Database Syst Rev; 2012 Feb; (2):CD008500. PubMed ID: 22336844
[TBL] [Abstract][Full Text] [Related]
10. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.
Hakoum MB; Kahale LA; Tsolakian IG; Matar CF; Yosuico VE; Terrenato I; Sperati F; Barba M; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD006649. PubMed ID: 29363105
[TBL] [Abstract][Full Text] [Related]
11. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
12. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
Farge D; Debourdeau P; Beckers M; Baglin C; Bauersachs RM; Brenner B; Brilhante D; Falanga A; Gerotzafias GT; Haim N; Kakkar AK; Khorana AA; Lecumberri R; Mandala M; Marty M; Monreal M; Mousa SA; Noble S; Pabinger I; Prandoni P; Prins MH; Qari MH; Streiff MB; Syrigos K; Bounameaux H; Büller HR
J Thromb Haemost; 2013 Jan; 11(1):56-70. PubMed ID: 23217107
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period.
Middleton P; Shepherd E; Gomersall JC
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD001689. PubMed ID: 33779986
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic prophylaxis for venous thromboembolism and 30-day outcomes among older patients hospitalized with heart failure: an analysis from the ADHERE national registry linked to Medicare claims.
Kociol RD; Hammill BG; Hernandez AF; Klaskala W; Mills RM; Curtis LH; Fonarow GC
Clin Cardiol; 2011 Nov; 34(11):682-8. PubMed ID: 22057910
[TBL] [Abstract][Full Text] [Related]
15. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial.
Schrag D; Uno H; Rosovsky R; Rutherford C; Sanfilippo K; Villano JL; Drescher M; Jayaram N; Holmes C; Feldman L; Zattra O; Farrar-Muir H; Cronin C; Basch E; Weiss A; Connors JM;
JAMA; 2023 Jun; 329(22):1924-1933. PubMed ID: 37266947
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.
Kahale LA; Matar CF; Hakoum MB; Tsolakian IG; Yosuico VE; Terrenato I; Sperati F; Barba M; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2021 Dec; 12(12):CD006649. PubMed ID: 34878173
[TBL] [Abstract][Full Text] [Related]
17. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Otten HM; Rutjes AW
Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Prophylactic Heparin Dosage Strategies and Risk Factors for Venous Thromboembolism in the Critically Ill Patient.
Reynolds PM; Van Matre ET; Wright GC; McQueen RB; Burnham EL; Ho PJM; Moss M; Vandivier RW; Kiser TH;
Pharmacotherapy; 2019 Mar; 39(3):232-241. PubMed ID: 30592541
[TBL] [Abstract][Full Text] [Related]
19. Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients.
Samuel S; To C; Ling Y; Zhang K; Jiang X; Bernstam EV
J Thromb Thrombolysis; 2023 Apr; 55(3):439-448. PubMed ID: 36624202
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Kahale L; Neumann I; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
Cochrane Database Syst Rev; 2014 Jun; (6):CD006649. PubMed ID: 24945634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]